Published in Bioinformation on November 23, 2012
Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotechnol (1997) 2.80
Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov (2002) 2.06
Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol (1998) 1.93
Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res (1996) 1.47
Mapping of RNA accessible sites by extension of random oligonucleotide libraries with reverse transcriptase. RNA (2001) 1.42
Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity. Nucleic Acids Res (2000) 1.22
Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol Biol (2007) 1.11
A computational method for resequencing long DNA targets by universal oligonucleotide arrays. Proc Natl Acad Sci U S A (2002) 1.02
Profiled support vector machines for antisense oligonucleotide efficacy prediction. BMC Bioinformatics (2004) 0.96
Artificial neural network prediction of antisense oligodeoxynucleotide activity. Nucleic Acids Res (2002) 0.95
Improved protein surface comparison and application to low-resolution protein structure data. BMC Bioinformatics (2010) 0.95
Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides. Biophys J (2005) 0.91
Functional genomics and target validation approaches using antisense oligonucleotide technology. Curr Opin Biotechnol (2001) 0.90
AOBase: a database for antisense oligonucleotides selection and design. Nucleic Acids Res (2006) 0.81
Antisense strategies in degenerative joint diseases: sense or nonsense? Adv Drug Deliv Rev (2006) 0.80
An ANN model for the identification of deleterious nsSNPs in tumor suppressor genes. Bioinformation (2011) 0.75